AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Hereditary Spastic Paraplegia

Recent research efforts aimed at curing Hereditary Spastic Paraplegia.

Last updated

Hereditary Spastic Paraplegia

Overview

Hereditary Spastic Paraplegia (HSP) is a large group of inherited neurological disorders in which the long nerve pathways controlling leg movement gradually malfunction or degenerate, causing leg stiffness (spasticity), weakness, balance problems, and increasing difficulty walking. “Pure” HSP mainly affects the legs and bladder function, whereas “complex” HSP can also involve developmental delay, intellectual disability, seizures, neuropathy, ataxia, vision problems, or other neurological features. Age of onset and rate of progression vary greatly by gene and subtype: some forms begin in childhood and can be severe, while others emerge in adulthood and progress slowly. HSP treatment and innovation review

There is currently no approved cure or broadly established disease-modifying therapy for HSP. Standard care is individualized symptom management, including physical and occupational therapy, stretching and exercise, mobility aids and orthotics, treatment of bladder symptoms, and medicines or procedures to reduce problematic spasticity; genetic diagnosis and counseling are also central to care. HSP treatment and innovation review

Scope of Recent Research (2020–present)

Research activity has accelerated, but HSP remains a fragmented field because more than 80 genetically distinct disorders can produce the HSP phenotype. The dominant questions are which subtypes can be treated by replacing a missing gene, which shared cellular problems—such as disrupted transport inside axons, mitochondrial dysfunction, or abnormal lipid metabolism—can be targeted with medicines, and which biomarkers can make small rare-disease trials interpretable. The clearest path toward potentially disease-altering treatment is currently in severe childhood AP-4-associated subtypes, especially SPG50 and SPG47, where AAV gene-replacement programs have reached human trials; however, no therapy has yet demonstrated that it cures HSP or restores lost nervous-system function in a controlled clinical study. SP-CERN clinical-trial readiness HSP treatment and innovation review

Major Breakthroughs and Emerging Therapies

The most important advance has been gene replacement for AP-4-associated HSP, a group of severe childhood disorders caused by loss of genes required for the adaptor protein-4 complex. In SPG50, caused by AP4M1 deficiency, researchers used an adeno-associated virus serotype 9 (AAV9)—a non-integrating viral delivery vehicle—to carry a functional AP4M1 gene into the nervous system. In patient fibroblasts, the treatment corrected abnormal trafficking of ATG9A, a cellular cargo protein; in mice, intrathecal treatment improved several disease-related behavioral measures, with earlier treatment and higher doses producing greater benefit. Toxicology studies in mice, rats, and nonhuman primates supported progression to human testing, although minimal-to-mild dorsal-root-ganglion toxicity was observed in animal studies. Preclinical AAV9/AP4M1 gene therapy

A 2024 single-patient phase 1 study provided the first published human evidence for an HSP gene therapy. A four-year-old child with SPG50 received intrathecal AAV9/AP4M1 gene therapy, called MELPIDA. Over one year, no serious adverse events were reported; transient neutropenia resolved without intervention, and investigators reported preliminary evidence consistent with stabilization and modest improvement on selected developmental and motor assessments. Because this was one child without a randomized control group, it cannot establish efficacy or prove reversal of disease, but it showed that a highly individualized HSP gene-replacement program could be developed and delivered within three years of diagnosis. Single-patient SPG50 AAV trial

A parallel AP-4 program targets SPG47, caused by AP4B1 deficiency. In a 2024 preclinical study, a single injection of AAV9 carrying AP4B1 into the cisterna magna—the cerebrospinal-fluid space near the base of the brain—restored disease-relevant ATG9A localization, reduced pathological abnormalities, improved motor dysfunction, and normalized plasma neurofilament light, a marker of neuronal injury, in an SPG47 mouse model. The study also reported no significant adverse events in a nonhuman-primate safety and biodistribution study, providing the basis for a first-in-human trial. Preclinical AP4B1 gene replacement

For more common adult-onset forms, researchers are pursuing small molecules that correct downstream cellular defects rather than replacing the gene directly. In SPG11 and SPG48 patient-derived cortical neurons, the experimental peptide P110 reduced excessive mitochondrial fragmentation, improved mitochondrial movement and energy measures, and reduced neurofilament abnormalities; restoring normal SPG11 expression also rescued several cellular defects. Mitochondrial-fission inhibition in SPG11/SPG48 neurons In SPG4, the most common autosomal-dominant subtype, a 2025 preprint reported that inhibiting HDAC6 with Tubastatin A improved microtubule acetylation, axonal degeneration, corticospinal-tract integrity, and gait-related outcomes in human organoid and mouse models. This is encouraging target-validation work, but it remains preclinical and has not yet undergone peer review or human testing. HDAC6 target in SPG4 preprint

Gene editing and RNA-based treatment are not yet established clinical approaches for HSP. CRISPR-Cas9 is being used principally as a research tool—for example, to create tagged SPG11 induced pluripotent stem-cell lines that allow scientists to study the disease protein spatacsin and identify potential therapeutic targets—rather than as a corrective treatment administered to patients. CRISPR-tagged SPG11 iPSC model

Clinical Trials and Experimental Approaches

The clinical pipeline is led by AP-4 gene-replacement programs. Elpida Therapeutics sponsors MELPIDA, an intrathecal AAV9/AP4M1 therapy for SPG50: the United States phase 1/2 study is listed as NCT05518188, and a subsequent multicenter phase 3 study with a matched prospective concurrent-control arm is listed as NCT06692712. A European phase 3 record for CT-MEL-03 lists Elpida as sponsor and describes recruitment planning in Spain and the United States. Published efficacy evidence remains limited to the earlier single-patient phase 1 report; no controlled phase 3 outcome has been published. CT-MEL-03 phase 3 record Single-patient SPG50 AAV trial

BlackfinBio’s BFB-101 is an AAV9/AP4B1 gene-replacement candidate for SPG47. The registered first-in-human study is a single-center, open-label phase 1/2 trial using stereotactic intra-cisterna-magna administration and is listed as NCT06948019. As of October 17, 2026, there are no published human outcome data for BFB-101. BFB-101 trial record

Other recent trials remain symptomatic rather than curative. A randomized trial in 36 people with pure HSP found that five weeks of gait-adaptability training on an augmented-reality treadmill improved obstacle-negotiation time, with benefit retained at follow-up. A small triple-blinded, randomized, placebo-controlled pilot study of dalfampridine reported greater improvement in timed walking in the treatment group, but larger studies are needed before its role in routine HSP care is clear. Gait-adaptability randomized trial Dalfampridine pilot trial

Methodologies and Scientific Approaches

HSP researchers increasingly combine patient-derived induced pluripotent stem cells, gene-edited isogenic cell lines, cortical-neuron cultures, organoids, and animal models to test therapies in systems that reflect the affected long motor axons. These platforms allow investigators to measure disease-relevant features such as axonal swellings, disrupted transport of cellular cargo, mitochondrial fragmentation, abnormal neurofilament accumulation, and impaired neuronal survival before moving candidates into animal safety studies. Preclinical AAV9/AP4M1 gene therapy Mitochondrial-fission inhibition in SPG11/SPG48 neurons HDAC6 target in SPG4 preprint

Clinical-readiness efforts now emphasize natural-history data, standardized motor assessments, blood and imaging biomarkers, wearable sensors, biobanking, and centralized data systems. SP-CERN collects longitudinal clinical data, biospecimens, and wearable-device information across 11 U.S. institutions, with the aim of defining progression rates and selecting outcome measures sensitive enough for very small trials. SP-CERN clinical-trial readiness

Leading Institutions and Funding

Boston Children’s Hospital, UT Southwestern Medical Center, The Hospital for Sick Children in Toronto, the U.S. National Institutes of Health, and the University of Sheffield have been especially prominent in AP-4-associated HSP research. Their collaborations produced the SPG50 preclinical program and first treated patient, as well as the SPG47 AP4B1 replacement program; Elpida Therapeutics and BlackfinBio are advancing the respective clinical candidates. Preclinical AAV9/AP4M1 gene therapy Single-patient SPG50 AAV trial Preclinical AP4B1 gene replacement

The Spastic Paraplegia Foundation supplied $750,000 in seed funding to establish SP-CERN. In 2025, the National Institutes of Health awarded SP-CERN an $8.4 million U54 grant, project number U54NS148312, to support a national consortium focused on therapeutic-target discovery, biomarkers, natural history, trial readiness, data sharing, and patient engagement for HSP and primary lateral sclerosis. SP-CERN funding update NIH RePORTER: SP-CERN

Strengths, Limitations, and Challenges

The field’s main strength is that certain HSP subtypes have unusually clear biological targets. In SPG47 and SPG50, disease is caused by loss of function of a single AP-4 gene, making replacement of that missing gene a rational strategy. The programs have also used a relatively strong translational sequence: patient-cell rescue, disease-model efficacy, animal toxicology, biomarker development, and early human dosing. Preclinical AAV9/AP4M1 gene therapy Preclinical AP4B1 gene replacement Single-patient SPG50 AAV trial

The central limitations are scientific uncertainty and scale. HSP is genetically and clinically diverse, so a therapy for one subtype may not help another; many patients already have established axonal injury by diagnosis, which may limit recovery even if the initiating genetic defect is corrected. The SPG50 human report involved one child, used extensive immunosuppression, and cannot separate treatment effect from individual variation or natural history. AAV programs must also establish durable benefit, appropriate dosing, immune safety, effects on sensory neurons such as dorsal-root ganglia, manufacturing capacity, and equitable access before they can be considered proven treatments. Single-patient SPG50 AAV trial Preclinical AAV9/AP4M1 gene therapy

Outlook and Future Directions

As of October 17, 2026, HSP is not close to a universal cure, but AP-4-associated HSP has moved from laboratory rationale to the first human gene-replacement trials, making it the most advanced curative-oriented area of the field. The milestones to watch are controlled MELPIDA results in SPG50, initial safety and biomarker findings from BFB-101 in SPG47, validation of natural-history and digital endpoints through SP-CERN, and confirmation that promising cell-model targets such as mitochondrial dynamics and microtubule regulation can be translated safely into people. A realistic near-term goal is subtype-specific slowing or stabilization of disease; restoration of lost function and broadly applicable cures will require longer follow-up and successful expansion beyond the small number of genetically tractable subtypes now in trials. SP-CERN clinical-trial readiness CT-MEL-03 phase 3 record BFB-101 trial record

References

Don't see your disease? Request a report